Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Platform Technology Partners

Platform Technology Partners boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 38.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,677 shares of the company’s stock after acquiring an additional 1,584 shares during the quarter. Platform Technology Partners’ holdings in Novo Nordisk A/S were worth $488,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of NVO. Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $28,000. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S during the third quarter worth about $42,000. Carolina Wealth Advisors LLC purchased a new position in Novo Nordisk A/S in the third quarter valued at about $48,000. Dunhill Financial LLC lifted its position in shares of Novo Nordisk A/S by 196.8% during the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after acquiring an additional 311 shares during the period. Finally, Albion Financial Group UT boosted its stake in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on NVO shares. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $86.39 on Friday. The company has a 50-day simple moving average of $91.86 and a 200-day simple moving average of $111.83. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a market cap of $387.66 billion, a PE ratio of 27.96, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 35.03% and a return on equity of 86.32%. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.16 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.